Biotech Values

[jbog]

Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals

Buy on weakness:

Teva's Enox Minor Deficiency Letter, Six-Month Delay, No Fundamental Change

12:39 pm ET 01/26/2011 - StreetInsider

Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA), PT $27. Canaccord analyst says, "We think m-enoxaparin s (MNTA/Sandoz generic Lovenox) sales are robust but Teva s generic enox may be out mid-2011. We think M356, MNTA/Sandoz generic Copaxone, is approvable without large clinical trials and MNTA will get positive clarity in the patent suit in H2/11. Our $27 target is based on a sum of the parts analysis." For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here. Shares of Momenta Pharmaceuticals closed at $12.50 yesterday, with a 52 week range of $10.77-$26.20